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Objective. To examine the distribution of stage at diagnosis for 12 cancers in Kuwait, to estimate stage-speciﬁc net survival at 1 and
5 years after diagnosis, and to assess diﬀerences in stage-speciﬁc survival between Kuwait and the United States. Material and
Methods. Data were obtained from the Kuwait Cancer Registry, for Kuwaiti patients diagnosed during 2000–2013, with follow-up
to 31 December 2015. *e distribution of Surveillance Epidemiology and End Results (SEER) Summary Stage for 12 malignancies
was examined. We estimated net survival by stage up to 5 years after diagnosis, controlling for background mortality with life
tables of all-cause mortality in the general population by single year of age, sex, and calendar period. Survival estimates were age-
standardised using the International Cancer Survival Standard (ICSS) weights. Results. Only 14.2% of patients were diagnosed at a
localised stage and 38.9% at the regional stage. *e proportion of patients with known stage was 88.9% during 2000–2004 but fell
to 59.4% during 2010–2013. During 2005–2009, 1- and 5-year survival for colon, rectal, breast, cervical, and prostate cancer was
about 90% or higher for patients diagnosed at the localised stage. During 2004–2009, the proportion of patients diagnosed at a
localised stage was lower in Kuwait than in the US for colon, breast, and lung cancer. Age-standardised 5-year net survival for all
stages combined was lower in Kuwait than the US for colon, lung, and breast cancer, but stage-speciﬁc survival was similar.
Conclusion. Since stage-speciﬁc survival is similar in Kuwait and the US, late stage at diagnosis is likely to be a major contributing
factor to the overall lower survival in Kuwait than in the US. Increasing public awareness of cancer risk factors and symptoms and
investment in early detection will be vital to reduce the proportion of patients diagnosed at a late stage and to improve survival.
1. Introduction
Stage at diagnosis, the anatomic extent of a disease, is a
major determinant of patients’ outcomes. [1] It is crucial in
predicting patients’ prognosis and to inform treatment
decisions, as well as to assess the eﬀect of public health
interventions such as screening programmes and educa-
tional or awareness campaigns, which aim to improve early-
stage diagnosis. Stage information is also valuable to help
plan the provision of cancer-related resources and services,
to monitor compliance to treatment guidelines, and to oﬀer
more detailed analyses of cancer outcomes [2].
Evaluation of the distribution of stage at diagnosis helps to
assess the intensity of diagnostic activity in a given country or
region. Examination of population-based survival trends by
stage at diagnosis helps to determine the eﬀectiveness of the
health system in oﬀering optimal, stage-speciﬁc treatment to
all patients. In Kuwait, net survival was lower than that in
other high-income countries [3]. Diﬀerences in the distri-
bution of stage at diagnosis are likely to be a key determinant
of these discrepancies. *e distribution of stage at diagnosis
for each cancer can also reﬂect the level of symptom
awareness as well as the thoroughness of the staging pro-
cedures within a region or country [4].
Population-based cancer survival by stage has never been
assessed in Kuwait. In order to provide a better un-
derstanding of cancer survival in the country, our study aims
to assess the distribution of stage at diagnosis in Kuwait for
12 cancers for which data are available and to estimate stage-
speciﬁc net survival at 1 and 5 years since diagnosis.
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Diﬀerences in stage-speciﬁc survival between Kuwait and
the United States will also be assessed.
2. Materials and Methods
We obtained data from the Kuwait Cancer Registry for all
adult Kuwaiti patients (aged 15–99 years) diagnosed during
2000–2013 with one of 18 malignancies [3, 5]. Data on stage
were available for 12 cancers: oesophagus, stomach, colon,
rectum, liver, pancreas, lung, melanoma, breast (women),
cervix, ovary, and prostate. All tumours were deﬁned by
anatomical site (topography) and coded to the International
Classiﬁcation of Diseases for Oncology (third edition, ICD-
O-3) [6] and its ﬁrst revision [7].
Data were assessed for quality and completeness
according to the protocol and standardised quality-control
procedures from the CONCORD programme for global
surveillance of cancer survival [8]. Records considered in-
eligible for survival analyses were excluded. Full details of
exclusions and data quality indicators have been published
[3].
Follow-up data were available until 31 December 2015.
Information on follow-up was obtained using a new method
[9] combining active and passive follow-up procedures,
which has been shown to be highly eﬀective in ascertaining
each patient’s vital status. Complete dates of death of de-
ceased cancer patients were obtained from the Central
Records Department of Births and Deaths, at Kuwait’s
Ministry of Health. When the vital status could not be
ascertained, the patients were considered lost to follow-up
and were censored from survival analyses.
We present the distribution of stage at diagnosis for the
12malignancies based on the Surveillance Epidemiology and
End Results (SEER) Summary Stage 2000, [10] which cat-
egorises the extent of the disease as localised, regional (with
lymph node involvement, or direct extension, or both), or
distant metastasis.
Patients were grouped into 3 consecutive calendar pe-
riods (2000–2004, 2005–2009, and 2010–2013). We esti-
mated stage-speciﬁc net survival only for cancers with at
least 10 patients in each stage category and calendar period.
Due to low numbers for most cancers, we present unstan-
dardised 1- and 5-year stage-speciﬁc survival estimates for
all ages combined.
Standardisation is crucial when comparing populations
that diﬀer with respect to age. Due to Kuwait’s relatively
small population and the rarer nature of some cancers,
however, age-standardisation of survival was only possible
for three cancers: colon, lung, and breast. To make com-
parisons between Kuwait and the US, stage-speciﬁc survival
estimates were obtained from the CONCORD-2 supple-
mentary studies on US data for colon, [11] lung [12], and
breast cancer [13]. To be able to compare results in Kuwait
with those in the US, survival was estimated for the calendar
period 2004–2009. For these analyses, we present age-
standardised stage-speciﬁc 5-year net survival, where
possible.
Net survival is the probability for cancer patients to
survive their cancer up to a given time following diagnosis
(e.g., 1 or 5 years), after correcting for competing causes of
death (background mortality). To control for background
mortality, we used life tables of all-cause mortality in the
general population. We used life tables by single year of age
(“complete” life tables), sex, calendar year of death, and
nationality (Kuwaiti; non-Kuwaiti) [8].
We used the Pohar–Perme estimator [14] to estimate net
survival, implemented with the programme stns [15] in Stata
version 14 [16]. *is estimator accounts for the fact that the
hazard of death due to causes other than cancer (competing
causes) is higher among older patients.
For patients diagnosed during 2000–2003 and 2004–
2009, the cohort approach was used to estimate survival. *e
cohort approach is considered the gold standard [17] and
can be used only when all patients in the cohort have had the
opportunity to be followed up for the full duration of the
follow-up required, in this case, ﬁve years. For patients
diagnosed during 2010–2013, the complete approach was
used because ﬁve years of follow-up data were not available
for all patients by December 2015. *is approach enables
survival estimates to be produced for recently diagnosed
patients [18].
Net survival estimates were age-standardised where
possible, using the International Cancer Survival Standard
(ICSS) weights, [19] in which age at diagnosis is categorised
into 5 groups: 15–44, 45–54, 55–64, 65–74, and 75–99 years.
*e 95% conﬁdence intervals (CI) for all unstandardised and
age-standardised estimates were derived assuming a normal
distribution, truncated to the range 0–100. Conﬁdence in-
tervals were constructed using standard errors calculated
using the Greenwood method [20]. When no deaths or
censorings occurred within 5 years, or if all patients died
(survival probability 1 or 0), a binomial approximation was
obtained for the upper and lower bounds of the CI.
3. Results
Colon (46.6%), rectal (39.7%), breast (49.4%), and cervical
cancer (36.2%) were most commonly diagnosed at regional
stage, while liver (29.9%), pancreas (48.3%), and lung
(41.2%) were mostly diagnosed at distant stage (Table 1). For
oesophagus (∼23%), stomach (∼32%), melanoma (∼22%),
and ovary (∼32%), the proportion of stage at diagnosis was
similar for both regional and distant stages. *e proportion
of men diagnosed with prostate cancer at localised stage
(25.7%) was similar to the proportion of men diagnosed at
distant stage (24.0%).
Overall, stage data were available for 74.1% of patients
diagnosed during 2000–2013. *is proportion decreased
from 88.9% in 2000–2004 to 59.4% in 2010–2013. Over this
14-year period, the highest proportion of unknown stage was
for liver (52.1%) and oesophageal cancer (42.2%); the lowest
was for colon (19.1%) and breast cancer (21.1%).
Between 2000–2004 and 2005–2009, when the avail-
ability of data on stage was reasonably high, a common trend
was observed in the stage distribution for most cancers: the
proportion of patients diagnosed at localised and regional
stage decreased, while that of distant and unknown stage
increased.*e exceptions were colon and liver cancer, where
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the proportion of patients diagnosed at localised stage
remained similar, and cancers of the breast and colon, where
the proportion diagnosed at a localised stage increased
slightly (18.7% to 22.4%, and 23.3 to 25.4%, respectively).
3.1. Stage-Speciﬁc Survival. In general, survival for all can-
cers was lower for patients diagnosed at more advanced stage
(Table 2). For patients diagnosed during 2010–2013, for
whom unknown stage at diagnosis was the highest, survival
for patients with unknown stage was either similar or
higher than the survival of all stages combined, for almost
all cancers. *is trend was also observed for patients di-
agnosed with unknown stage during 2000–2004 and
2005–2009.
During 2005–2009, one-year survival for colon, rectal,
breast, and ovarian cancer was generally similar for patients
diagnosed at localised or regional stage (Figure 1). One- and
ﬁve-year survival for prostate, rectal, breast, cervical, and
prostate cancer was high (almost 90% or higher) and rel-
atively similar, for patients diagnosed at localised stage. Five-
year survival for all cancers was relatively low, ranging from
43.5% for prostate to 0% for stomach, for patients diagnosed
at distant stage.
During the same period, the greatest diﬀerence in ﬁve-
year survival between regional and distant stage at diagnosis
was observed for colon, rectum and breast cancer (>50%),
followed by prostate, stomach, and ovarian cancer (about
30%). For some of the more lethal cancers, the diﬀerence in
one-year survival between regional and distant stage was
Table 1: Number of patients and distribution of SEER Summary
Stage at diagnosis, by cancer and calendar period; Kuwaiti adults
(15–99 years).
Cancer site
No. of cases
2000–2004 2005–2009 2010–2013 All periods
(n) (%) (n) (%) (n) (%) (n) (%)
Oesophagus
Localised 6 22.2 2 8.3 3 7.7 11 12.2
Regional 10 37.0 6 25.0 4 10.3 20 22.2
Distant 4 14.8 8 33.3 9 23.1 21 23.3
Unknown 7 25.9 8 33.3 23 59.0 38 42.2
Total 27 24 39 90
Stomach
Localised 2 3.4 2 2.5 2 2.9 6 2.9
Regional 32 54.2 23 29.1 19 27.5 74 35.8
Distant 13 22.0 34 43.0 13 18.8 60 29.0
Unknown 12 20.3 20 25.3 35 50.7 67 32.4
Total 59 79 69 207
Colon
Localised 25 10.6 34 10.5 25 7.2 84 9.3
Regional 162 68.4 151 46.5 110 31.8 423 46.6
Distant 39 16.5 99 30.5 90 26.0 228 25.1
Unknown 11 4.6 41 12.6 121 35.0 173 19.1
Total 237 325 346 908
Rectum
Localised 19 22.4 18 13.9 13 11.3 50 15.2
Regional 48 56.5 53 40.8 30 26.1 131 39.7
Distant 9 10.6 31 23.9 17 14.8 57 17.3
Unknown 9 10.6 28 21.5 55 47.8 92 27.9
Total 85 130 115 330
Liver
Localised 3 4.4 5 4.7 4 4.6 12 4.6
Regional 17 25.0 8 7.6 10 11.5 35 13.4
Distant 15 22.1 39 36.8 24 27.6 78 29.9
Unknown 33 48.5 54 50.9 49 56.3 136 52.1
Total 68 106 87 261
Pancreas
Localised 2 3.5 4 4.4 1 1.1 7 2.9
Regional 23 40.4 15 16.5 15 16.3 53 22.1
Distant 22 38.6 49 53.9 45 48.9 116 48.3
Unknown 10 17.5 23 25.3 31 33.7 64 26.7
Total 57 91 92 240
Lung
Localised 9 5.0 7 3.7 2 1.1 18 3.2
Regional 78 43.6 43 22.5 30 16.0 151 27.1
Distant 66 36.9 84 44.0 80 42.6 230 41.2
Unknown 26 14.5 57 29.8 76 40.4 159 28.5
Total 179 191 188 558
Melanoma
Localised 1 20.0 1 14.3 1 16.7 3 16.7
Regional 2 40.0 1 14.3 1 16.7 4 22.2
Distant 1 20.0 3 42.9 0 0.0 4 22.2
Unknown 1 20.0 2 28.6 4 66.7 7 38.9
Total 5 7 6 18
Breast
Localised 117 18.7 213 22.4 149 15.1 479 18.7
Regional 431 68.9 461 48.6 374 37.9 1,266 49.4
Distant 47 7.5 126 13.3 102 10.3 275 10.7
Unknown 31 5.0 149 15.7 361 36.6 541 21.1
Total 626 949 986 2,561
Table 1: Continued.
Cancer site
No. of cases
2000–2004 2005–2009 2010–2013 All periods
(n) (%) (n) (%) (n) (%) (n) (%)
Cervix
Localised 19 30.7 15 25.4 6 14.3 40 24.5
Regional 28 45.2 20 33.9 11 26.2 59 36.2
Distant 5 8.1 3 5.1 2 4.8 10 6.1
Unknown 10 16.1 21 35.6 23 54.8 54 33.1
Total 62 59 42 163
Ovary
Localised 10 16.1 10 10.9 3 4.5 23 10.4
Regional 30 48.4 23 25.0 18 26.9 71 32.1
Distant 16 25.8 36 39.1 19 28.4 71 32.1
Unknown 6 9.7 23 25.0 27 40.3 56 25.3
Total 62 92 67 221
Prostate
Localised 27 23.3 43 25.4 61 27.2 131 25.7
Regional 36 31.0 21 12.4 15 6.7 72 14.2
Distant 33 28.5 53 31.4 36 16.1 122 24.0
Unknown 20 17.2 52 30.8 112 50.0 184 36.2
Total 116 169 224 509
All cancers
Localised 240 15.2 354 15.9 270 11.9 864 14.2
Regional 897 56.7 825 37.1 637 28.2 2,359 38.9
Distant 270 17.1 565 25.4 437 19.3 1,272 21.0
Unknown 176 11.1 478 21.5 917 40.6 1,571 25.9
Total 1,583 2,222 2,261 6,066
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Figure 1: Continued.
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substantially smaller (around 25%), e.g., for stomach (70.4%
vs. 44.7%) and pancreatic cancer (47.1% vs. 18.6%).
3.2. Comparisons between Kuwait and the United States.
During 2004–2009, the proportion of patients diagnosed at
localised stage was substantially lower in Kuwait than in the
US for colon (10.7% vs. 37.8%) and breast (21.9% vs. 59.1%),
while the proportions of regional, distant and unknown
stages were higher, with diﬀerences ranging from 5% to 21%
(Figure 2). For lung cancer, the proportion of localised stage
was much lower in Kuwait than in the US (3.5% vs. 17.7%);
however, the proportion was similar in the two countries for
regional (22.5% vs. 23.4%) and distant stage (47.6% vs.
50.0%).
Age-standardised ﬁve-year net survival in Kuwait for all
stages combined for colon (50.6%), lung (15.3%), and breast
(70.8%) was lower than in the US (64.6%, 19.0%, and 88.6%,
respectively) (Table 3).
For colon cancer, stage-speciﬁc ﬁve-year net survival was
similar in Kuwait and the US for both regional disease
(73.0% vs. 70.2%) and distant stage (13.7% vs. 13.8%).
For lung cancer, the only age-standardised stage-speciﬁc
survival estimate available for Kuwait was for distant stage.
Survival for patients diagnosed at distant stage in Kuwait was
somewhat higher than in the US (8.0% vs. 4.8%). For breast
cancer, stage-speciﬁc survival was generally similar in
Kuwait and the US: slightly lower for localised stage (94.4%
vs. 98.3%) and slightly higher for distant stage (28.4% vs.
24.5%). For regional stage, stage-speciﬁc survival in Kuwait
was lower than in the US (75.7% vs. 82.3%).
4. Discussion
*is is the ﬁrst population-based study to date in Kuwait to
assess the distribution of stage at diagnosis and stage-speciﬁc
survival, over a 14-year period, for up to 12 malignancies.
Examining the distribution of stage at diagnosis is essential
to interpret the variations in survival over time and helps
identify cancers for which earlier diagnosis can achieve the
greatest beneﬁt. Diﬀerences in population-based survival
between diﬀerent populations or regions may also be partly
explained by diﬀerences in stage of disease at diagnosis.
[21, 22] *is study produced stage-speciﬁc net survival es-
timates up to 5 years for colon, lung, and breast cancer,
taking into account the diﬀerences in the age proﬁle of
cancer patients and the risk of death from other causes, thus
enabling robust comparisons of stage-speciﬁc survival over
time.
Age-standardisation is essential to compare survival over
time, or between diﬀerent regions, since net survival can
vary considerably by age, and the age structure of cancer
patients diﬀers between countries and over time. However,
due to the small number of patients available for analysis in
Kuwait, age-standardisation of the survival estimates for
each stage category was not possible for many cancers.
Comparisons of stage-speciﬁc survival over time in Kuwait
were therefore performed using unstandardised estimates.
During 2000–2013, the stage at diagnosis was known for
74% of the patients. *e proportion of patients with known
stage decreased over the 14-year period, reaching its lowest
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Figure 1: Trends in unstandardised net survival (NS, %) at 1 and 5 years, by SEER Summary Stage at diagnosis, Kuwait 2005–2009.
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(59%) during 2010–2013. *e mean age and the age dis-
tribution were generally similar for patients with known and
unknown stage during 2010–2013, except for pancreatic
cancer, where the proportion of patients older than 85 years
was higher among patients with unknown stage.*e survival
for patients with known stage, for most cancers, was also
generally similar to that for patients with unknown stage.
*e unavailability of information on stage in this case is
therefore less likely due to physicians’ staging practices or to
patients not being medically ﬁt for staging and treatment. A
plausible explanation could be that more patients are re-
ceiving their ﬁrst treatment abroad and therefore are not
staged in Kuwait. Receiving treatment abroad is a service
provided by the government, covering full treatment costs.
With the Ministry of Health’s increased budget for overseas
treatment in 2009, more patients have been utilising this
option [23]. *e increased proportion of unknown stage for
patients diagnosed during 2010–2013 could thus be due to
more patients receiving treatments abroad.
During 2005–2009, 1- and 5-year stage-speciﬁc survival
for patients diagnosed at localised stage was about 90% or
higher for colon, rectal, breast, cervical, and prostate cancer.
In Kuwait, these cancers are most commonly diagnosed at
regional stage, and the proportion of patients diagnosed at
localised stage is low, ranging from 25.4% for prostate to
10.5% for colon cancer. Furthermore, the largest diﬀerence
in survival was observed between patients diagnosed at
regional and distant stages. *is diﬀerence in ﬁve-year net
survival was most evident (greater than 50%) for cancers of
the colon, rectum, and breast, followed by those of prostate,
stomach, and ovary, where this diﬀerence was about 30%.
*is further highlights the cancers for which early diagnosis
is important and where greater eﬀorts are essential to ensure
that more patients are diagnosed at an earlier stage, par-
ticularly for cancers for which early detection tests and
procedures are available [24].
For colon, lung, and breast, we compared the survival in
Kuwait to that in the US, where the survival is among the
highest worldwide [5]. We used the calendar period, cancer
deﬁnitions, data quality control procedures, and analytical
methods used for the CONCORD-2 supplementary analyses
of stage-speciﬁc survival for the US [25], allowing, therefore,
appropriate and robust comparisons.
Stage-speciﬁc survival for colon cancer in Kuwait was
similar to survival in the US for patients diagnosed at
regional and distant stages. Due to low number of patients,
it was not possible to estimate stage-speciﬁc survival for
localised stage in Kuwait; however, the proportion of
patients diagnosed at localised stage, which generally
entails good prognosis, was substantially higher in the US
(37.8%) than in Kuwait (10.7%). *is diﬀerence in the
proportion of patients diagnosed at early stage could
partially explain the lower survival for all stages combined
observed in Kuwait.
For lung cancer, survival for all stages combined was
lower in Kuwait (15.3%) than in the US (19.0%). Compar-
isons of stage-speciﬁc estimates were only possible for
distant stage. *e proportion of distant stage, however,
constitutes the majority of lung cancer patients, which was
similar in Kuwait and the US (47.6% and 50.9%, re-
spectively). Stage-speciﬁc survival for distant stage was
somewhat higher in Kuwait (8.0%) than in the US (4.8%).
*erefore, the lower survival for all stages combined in
Kuwait is probably attributable to diﬀerences in the pro-
portion of patients diagnosed at the localised stage, which
was substantially lower in Kuwait (3.5%) than in the US
(17.7%). Further investigation is necessary to explain the
higher survival for patients diagnosed at distant stage in
Kuwait. While the introduction of targeted therapies has
improved the treatment of advanced lung cancer, [26] the
very high cost of these treatments can limit their adoption
and application [27]. In Kuwait, treatment is fully covered by
the government, so ﬁnancial limitations will probably have
little eﬀect on the usage of such therapies. In the US, medical
insurance coverage can limit patients’ access to some of the
less cost-eﬀective treatments, particularly for patients with a
Table 3: Number of patients, SEER Summary Stage distribution (%), and age-standardised 5-year net survival (NS, %), for adults in Kuwait
(Kuwaiti) and the United States (all races), 2004–2009.
Cancer SEER SS
Kuwait United States
No. of patients (%) NS (%) 95% CI No. of patients (%) NS (%) 95% CI
Colon
All stages 365 50.6 43.4–57.8 534,721 64.6 64.4–64.9
Localised (10.7) — — (37.8) 89.7 89.4–90.0
Regional (46.9) 73.0 66.8–79.3 (34.9) 70.2 69.8–70.6
Distant (29.9) 13.7 7.7–19.7 (19.3) 13.8 13.4–14.1
Unknown (12.6) — — (7.9) 49.4 48.6–50.2
Lung
All stages 227 15.3 10.7–20.0 955,184 19.0 18.8–19.1
Localised (3.5) — — (17.7) 55.1 54.7–55.5
Regional (22.5) — — (23.4) 26.4 26.0–26.7
Distant (47.6) 8.0 3.8–12.2 (50.9) 4.8 4.7–4.9
Unknown (26.4) — — (8.0) 13.8 13.4–14.3
Breast
All stages 1,092 70.8 64.0-77.6 926,271 88.6 88.4–88.8
Localised (21.9) 94.4 88.4–100.0 (59.1) 98.3 98.1–98.6
Regional (51.0) 75.7 67.2–84.3 (30.2) 82.3 81.9–82.7
Distant (12.5) 28.4 22.3–34.5 (5.2) 24.5 23.7–25.2
Unknown (14.7) 65.7 53.6–77.9 (5.4) 72.6 71.9–73.4
SEER SS: Surveillance, Epidemiology, and End Results Summary Stage; CI: conﬁdence interval.
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poor prognosis.*erefore, to understand these diﬀerences in
stage-speciﬁc survival, it would be necessary to assess the
diﬀerences in the modality and access to treatment between
the countries.
For breast cancer, the diﬀerence in early stage at di-
agnosis may explain the lower survival observed for all stages
combined between Kuwait (70.8%) and the US (88.6%). *e
lower proportion of women diagnosed at a localised stage
could be due to lack of screening. Unlike the US, screening
programmes for breast cancer were not available for women
diagnosed during 2004–2009, since screening oﬃcially
commenced in Kuwait in 2014 [28]. Diﬀerences in early
stage diagnoses between the two countries could also be due
to other factors such as the population’s awareness of early
symptoms, knowledge of risk factors, and access to timely
diagnostic tests.
Survival in Kuwait was also lower than in several other
high-income countries [3]. *is could also be attributable to
diﬀerences in diagnostic activity and the tendency towards
later diagnosis in Kuwait. Diﬀerences in survival can arise
due to several other reasons that require further in-
vestigation: prevalence of comorbidities; attitudes and be-
haviours towards treatment; diﬀerences in primary care
systems; delays in access to treatment; and the eﬃcacy of
treatment.
*e small population of Kuwait limited our analyses,
where the estimation of stage-speciﬁc survival by sex was not
possible due to the small number of patients available for
analysis. *e interpretation of stage-speciﬁc trends over the
14-year period (2000–2013) was also aﬀected by a high
proportion of unknown stage, which was higher for patients
diagnosed during 2010–2013 than for patients diagnosed in
earlier years.
5. Conclusion
Complete information on stage at diagnosis is required in
order to assess the eﬀectiveness of cancer control strategies.
In Kuwait, the quality of and completeness of stage data can
be improved in several ways, the most urgent of which is
investing in the Kuwait Cancer Registry. *is would include
increasing the labour force, enabling the staﬀ to cope with
the increasing number of diagnoses and continuously
updating the staﬀ’s knowledge and skills in order to adapt to
changes in staging and coding guidelines. Another way
would be to implement more systematic procedures for
retrieving patients’ medical notes from diﬀerent hospitals,
particularly in the case of those receiving treatment abroad.
Finally, investing in an electronic medical record system
where all patients’ medical data would be stored electron-
ically could improve the timelines substantially and maxi-
mise eﬃciency in accessing patients’ data.
*is study supplements our previous knowledge on the
eﬀect of stage at diagnosis as a major determinant of out-
come. Our study also shows that a low proportion of early-
stage diagnoses could be amajor contributing factor to lower
survival in Kuwait than in other high-income countries.
Investment in early detection and increasing public
awareness of cancer risk factors and symptoms will be vital
to reduce the proportion of late-stage diagnoses and, ulti-
mately, improve outcomes.
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